Ensign Peak Advisors
ITRM

Ensign Peak Advisors’s Iterum Therapeutics ITRM Stock Holding History

Ensign Peak Advisors’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-12,657
Closed -$515K – 1684
2020
Q1 		$515K Sell
12,657
-2,728
-18% -$115K ﹤0.01% 1395
2019
Q4 		$1.04M Buy
+15,385
New +$751K ﹤0.01% 1322

Other funds holding ITRM

CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ML
McAdam LLC Philadelphia, Pennsylvania $2.22B AUM 16.98% 1-Year Est. Return
BG
Bollard Group Boston, Massachusetts $3.39B AUM 1.06% 1-Year Est. Return
CCMW
Cypress Capital Management (Wyoming) Sheridan, Wyoming $108M AUM 54.47% 1-Year Est. Return

Ensign Peak Advisors's ITRM Position: Q2 2020 in Review

Ensign Peak Advisors sold out of Iterum Therapeutics (ITRM) in Q2 2020, closing a stake of 12,657 shares — an estimated $515K sold.

Ensign Peak Advisors first reported a position in ITRM in Q4 2019 and held it in 2 quarters. The position peaked at $1.04M in Q4 2019. 10 funds tracked by Wall St. Rank hold ITRM as of Q2 2020.

  • Ensign Peak Advisors reported no remaining Iterum Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Ensign Peak Advisors sold 12,657 Iterum Therapeutics shares in Q2 2020, an estimated $515K.
  • Ensign Peak Advisors first reported a position in Iterum Therapeutics in Q4 2019 and held it in 2 quarters.
  • Ensign Peak Advisors's Iterum Therapeutics position peaked at $1.04M in Q4 2019.
  • 10 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2020.

Based on Ensign Peak Advisors's 13F filing for Q2 2020, filed 12 Aug 2020.